Welcome to the e-CCO Library!

P588: Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kuehbacher T.*1, Abu Hashem R.1, Langel N.1, Schreiber S.2, Drvarov O.1

Created: Wednesday, 20 February 2019, 10:36 AM
P589 Longer-term outcomes in patients with Crohn’s disease who are primary non-responders to anti-TNF in a single UK centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. HODGES, J. Saunders, F. Betteridge

Created: Thursday, 30 January 2020, 10:12 AM
P589: A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Kantasiripitak1, E. Dreesen*1, I. Detrez1, S. Stefanović2, D. Drobne2, S. Vermeire3,4, M. Ferrante3,4, A. Gils1

Created: Friday, 22 February 2019, 9:41 AM
P589: Adherence to medical treatment in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Jardak1*, L. Hamzaoui1,2,3, K. Agar2, M. Medhioub2, A. Khsiba2, M.M. Azouz2

Created: Thursday, 21 February 2019, 9:14 AM
P589: Effectiveness of partial enteral nutrition to treat adults with Crohn's Disease who lost response to biological therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nardone, O.M.(1)*;Calabrese, G.(2);Alfonsi, L.(3);Rispo, A.(2);La Mantia , A.(2);Fierro, G.(2);Ferrante, M.(2);Testa, A.(2);Guarino, A.D.(2);D'Alessandro, E.(2);Pasanisi, F.(3);Castiglione, F.(2);
Created: Friday, 14 July 2023, 11:05 AM
P589: Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Paramsothy S.*1,2, Paramsothy R.3, Kamm M.4, Kaakoush N.5, Mitchell H.6, Rubin D.2, Castaño-Rodríguez N.6

Created: Wednesday, 20 February 2019, 10:36 AM
P589: Stable Trends in Radiation Exposure Amongst Patients with a New Diagnosis of Inflammatory Bowel Disease at an Irish Tertiary Referral Hospital
Year: 2021
Source: ECCO'21 Virtual
Authors: Matthews, T.J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P589: Total thiopurine exposure and impact on the development of keratinocyte carcinomas in Inflammatory Bowel Disease patients; a case control study
Year: 2022
Source: ECCO'22
Authors: Jansen, F.M.(1);Lubeek, S.(2);den Broeder, N.(3);Savelkoul, E.(1);Marcus, C.(1);Hoentjen, F.(1,4);van Dop, W.(1);
Created: Friday, 11 February 2022, 3:56 PM
P590 Outcomes of patients treated with sequential anti-TNF therapy in a tertiary referral centre
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Rowan, J. O’Donnell, N. Cullen, A. O’Toole, K. Boland

Created: Thursday, 30 January 2020, 10:12 AM
P590: ADVANCED-UC TRIAL: AppenDectomy Vs ANti TNF-a in inducing Clinical and EnDoscopic remission in left-sided Ulcerative Colitis – A Randomized Clinical Trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Luglio, G.(1)*;Rispo, A.(2);Tropeano, F.P.(3);Cricrì, M.(2);Castiglione, F.(2);De Palma, G.D.(2);
Created: Friday, 14 July 2023, 11:05 AM
P590: Laparoscopy in Crohn’s disease: Learning curve and current practice
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Mege1,2*, F. Michelassi1

Created: Thursday, 21 February 2019, 9:14 AM
P590: Reasons for discontinuation and switch of biologic therapy in IBD: findings from a large international observational study (03)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sebastian S.*1, Lewis J.D.2, Siegmund B.3, Wolf D.4, Siegel C.A.5, Lichtenstein G.2, Louis E.6, Hebuterne X.7, Ginsburg P.M.8, Ostrov A.9, Ricci M.Q.10, Bernsen M.11, Shafran I.12, Nancey S.13, Moran G.14, Teich N.15, Lal S.16, Kiszka-Kanowitz M.17, Murugesan S.18, Moum B.19, Dolin P.20

Created: Wednesday, 20 February 2019, 10:36 AM
P590: Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel
Year: 2022
Source: ECCO'22
Authors: Hansen, R.(1);Meade, S.(2);Torrente, F.(3);Kammermeier, J.(4);Croft, N.M.(5);de Ridder, L.(6);Wilson, D.C.(7);Klomberg, R.(6);Turner, D.(8);Martín-de-Carpi, J.(9);Bronsky, J.(10);Benchimol, E.(11);Amil-Dias, J.(12);Mack, D.R.(13);Walker, G.(14);Powar, M.(15);Burgess, N.(16);van Ommen, C.H.(17);Irving, P.M.(18);Samaan, M.(18);
Created: Friday, 11 February 2022, 3:56 PM
P590: Which biomarkers have an effect on therapeutic vedolizumab drug levels? A retrospective analysis from a London Tertiary Centre.
Year: 2021
Source: ECCO'21 Virtual
Authors: Bancil, A.(1);Stevens, M.(2);Kok, K.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P591 Therapeutic management in inflammatory bowel disease: Differences in two IBD inception cohorts: 1991–93 and 2010–11 enrolled in the north-west of Spain
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.L. De Castro Parga, V. Hernández, L. Sanroman, J.R. Pineda, M. Figueira, J. Martinez-Cadilla, S. Pereira, J.I. Rodriguez-Prada

Created: Thursday, 30 January 2020, 10:12 AM
P591: Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB).
Year: 2021
Source: ECCO'21 Virtual
Authors: Sassaki, L.Y.(1);Magro, D.O.(2);Saad-Hossne, R.(3);Baima, J.P.(1);Flores, C.(4);Correia, L.P.D.M.P.(5);Ferrari, M.D.L.D.A.(6);Zacharias, P.(7);Feitosa, M.R.(8);Santos, C.H.M.(9);Lins Neto, M.A.D.F.(10);Quaresma, A.B.(11);Lima Junior, S.F.(12);Vasconcelos, G.B.S.(13);Cassol, O.(14);Pinto, A.D.S.(15);Kurachi, G.(16);Goncalves Filho, F.D.A.(17);Gasparini, R.G.(18);Furlan, T.K.(19);Catapani, W.(20);Coy, C.S.R.(2);Menegassi, V.D.S.(21);Colombo, M.M.(22);Froes, R.D.S.B.(23);Teixeira, F.V.(3);Moraes , A.C.(24);Santana , G.O.(25);Parente, J.M.L.(26);Vilela , E.G.(27);Kotze , P.G.(7);
Created: Wednesday, 2 June 2021, 4:12 PM
P591: Biological therapies and small molecules show to be efficacious in patients with moderate-to-severe ulcerative proctitis.
Year: 2022
Source: ECCO'22
Authors: Lemmens, P.(1);Guedelha Sabino, J.(1,2);Dubois, E.(1);Verstockt, B.(1,2);Vermeire, S.(1,2);Ferrante, M.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P591: Gastroenterologist performed point-of-care gastrointestinal ultrasound improves patient understanding of disease activity, symptomatology, management decisions and clinical outcomes
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Friedman1*, A. Asthana1,2, S. Knowles3, A. Robbins4, P. Gibson1

Created: Thursday, 21 February 2019, 9:14 AM
P591: Low donor microbial engraftment after combined endoscopic and oral faecal microbiota transplant (FMT) in patients with antibiotic dependent pouchitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Herfarth*1, E. L. Barnes1, M. D. Long1, K. L. Isaacs1, T. Leith2, M. Silverstein3, Y. Gerardin3, Z. Kassam3

Created: Friday, 22 February 2019, 9:41 AM
P591: Negative impact of high body mass index on the efficacy of anti-TNFα agents in patients with Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hamoir, F.(1)*;De Leuze, F.(1);Denis, M.(1);De Vroey, B.(1);De Suray, N.(1);Burnet, G.(1);Piessevaux, H.(1);Dewit, O.(1);
Created: Friday, 14 July 2023, 11:05 AM